Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody - Zou, J; Li, T; Huang, X (Ann Rheum Dis, 2014)
et al.